With the updated, BA.4/5-focused boosters, researchers at the Galveston-based University of Texas Medical Branch found that antibodies were about four times lower against BQ.1.1 compared to BA.5, according to a small study published Dec. 6 in Nature. Against XBB.1, antibodies were eight times lower among the 29 analyzed blood samples.
A different study published the same day in The Lancet, which tracked the vaccine’s effectiveness versus XBB sublineages, found similar results. Both studies were small, as they analyzed about 30 samples each, but they offer the first glimpse at how the bivalent boosters authorized in early fall act against new variants.
BQ.1.1 is the leading subvariant with 31.9 percent of infections, and XBB and BA.2.75.2 follow behind with 5.5 percent and 0.5 percent, according to CDC data. Subvariant XBB.1 is not tracked by the CDC.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
